MedTrace Logo

Weekly Topotecan With Docetaxel in Recurrent Small Cell Lung Cancer

NCT00315211 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2018-08-20

No results posted yet for this study

Summary

The purposes of this study are:

* To determine the overall response rate of patients treated with at least 2 cycles of this regimen.
* To determine the feasibility and toxicity of the combination of topotecan and docetaxel.

Conditions

  • Mediastinal Neoplasms

Interventions

DRUG

Intravenous Topotecan

Topotecan 3 mg/m2 IV over 30 minutes on Days 1 and 8 every 21 days

DRUG

Intravenous Docetaxel

Docetaxel 30 mg/m2 IV over 60 minutes on Days 1 \& 8 of a 21 day cycle

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • Aultman Health Foundation

    lead OTHER

Principal Investigators

  • Raza Khan, MD · Aultman Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-11-30
Primary Completion
2007-06-30
Completion
2007-11-08

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00315211 on ClinicalTrials.gov